Senator for Economic Affairs Franziska Giffey visits the Klosterfrau Berlin production site

As part of the current “Made in Berlin” tour, Senator for Economic Affairs Franziska Giffey visited Klosterfrau Berlin GmbH, the Klosterfrau Group’s largest production site. During the tour, she is visiting projects and initiatives on site to engage in dialogue with businesses and employees. The shared aim is to establish Berlin as a leading centre of innovation and production for the pharmaceutical and biotech industries.

As part of the Berlin Pharmaceutical Talks, which began back in January 2025, the “Berlin Declaration: Future of Pharmaceuticals” was signed. Through investment support for production, research and development, securing and attracting skilled workers, and improving local conditions – including infrastructure and the removal of regulatory barriers – Berlin is set to become a leading centre for innovation and production. The talks focus, among other things, on sustainability, location development and improving the regulatory framework.

Klosterfrau has had deep roots in Berlin for over 55 years, and in recent decades Klosterfrau Berlin GmbH has developed into an integrated pharmaceutical industrial site. Today, across 45,000 square metres, we produce medicinal lozenges, liquid medicinal forms and sterile disposable syringes in accordance with the strictest GMP and FDA guidelines (Good Manufacturing Practice & Food and Drug Administration). Sustainable production and innovation in new technologies are key drivers for the employees at Klosterfrau Berlin.

To safeguard existing jobs and create new ones, the Klosterfrau Group is investing approximately €60 million over four years in the construction of modern production facilities at its Berlin site. The facilities are characterized by innovative sustainability technologies for energy saving, efficiency and recovery. As the first sub-project, the new syringe plant commenced production in June 2025 as a highly automated sterile facility with 1,200 m² of cleanroom space for innovative pre-filled syringe systems. The opening of the new ‘medical lozenges’ facility will follow two years later. A new facility for the manufacture and packaging of medical sweets is scheduled to go into operation in early 2027.

A particular highlight of Senator Giffey’s visit was the professional exchange on innovation and production. During the tour of the factory premises, she was given an insight into the production facilities of the confectionery plant, where the hard sweets are manufactured. Klosterfrau Berlin GmbH was delighted to have the opportunity to show the Senator around the production site and to continue the important dialogue on the future of Germany as a pharmaceutical hub.

“Klosterfrau Berlin GmbH has been an integral part of Berlin’s pharmaceutical sector for many decades and is a striking example of how a long-standing tradition can pave the way for forward-looking pharmaceutical production. The investments in modern production facilities and sustainable technologies represent a strong commitment to Berlin as a hub for innovation and industry. In doing so, the company is providing a significant boost to industrial value creation and employment in our city,” said Franziska Giffey, Senator for Economics, Energy and Public Enterprises.